title: Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy.
abstract: OBJECTIVE
  Patients with antibody deficiency rely on immunoglobulin products for protection against many vaccine-preventable diseases. We measured antibody titers against Bordetella pertussis and Neisseria meningitidis in patients receiving immunoglobulin (IG) therapy to determine if they have any protection against infections from these organisms.
  
  
  METHODS
  In an unblinded, prospective assessment we measured antibody titers against B. pertussis filamentous hemagglutinin (FHA) and pertussis toxin (PT) antigens and N. meningitidis serogroups A, C, W-135, and Y in patients receiving immunoglobulin therapy for primary immune deficiency (PI). We measured steady state levels in patients receiving subcutaneous immunoglobulin therapy while in patients receiving intravenous immunoglobulin therapy we measured titers immediately before and after infusion to more clearly define the contribution of the infused product.
  
  
  RESULTS
  Thirty subjects, 17 females and 13 males, participated in the study, 22 were receiving intravenous IG products and 8 were receiving subcutaneous IG products. Diagnoses included common variable immunodeficiency in 12, combined immunodeficiency in 6, specific antibody deficiency in 6, X-linked agammaglobulinemia in 4 and ataxia telangiectasia and hyper-IgE syndrome in one each. All subjects had detectable IgG antibodies against the pertussis antigens measured and most had antibody to the meningococcus serotypes measured. However, only 26.6 % had protective levels (>= 2 mcg/mL) against serogroup C at trough or steady state.
  
  
  CONCLUSIONS
  Patients receiving immunoglobulin therapy have antibodies against B. pertussis and most of them have antibodies against the four measured serogroups of N. meningitidis. There is significant variability in the levels of antibody between patients and the low titers against group C may suggest a role for active immunization in those who may respond to conjugated polysaccharide vaccine administration.
authors: Division of General Pediatrics, Children's Hospital Los Angeles, 4650 Sunset Blvd, MS # 68, Los Angeles, CA, 90027, USA.
authors: Etai
authors: E
authors: Adam
authors: Joseph A
authors: JA
authors: Church
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D001886:Bordetella pertussis / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000628:therapy*; D008297:Male; D008585:Meningitis, Meningococcal / Q000517:prevention & control; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000276:immunology*; D011446:Prospective Studies; D065288:Serogroup; D014917:Whooping Cough / Q000517:prevention & control; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D016756:Immunoglobulins, Intravenous
references: J Clin Immunol. 2012 Dec;32(6):1180-92
references: 22730009
references: N Engl J Med. 1977 Sep 29;297(13):686-91
references: 408682
references: J Clin Pathol. 2006 Nov;59(11):1191-3
references: 17071803
references: Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
references: 20463105
references: Pediatrics. 2009 Sep;124(3):e484-8
references: 19706589
references: J Allergy Clin Immunol. 2010 Jan;125(1):198-202
references: 19962745
references: Vaccine. 1998 Dec;16(20):1901-6
references: 9796041
references: Clin Vaccine Immunol. 2006 Feb;13(2):266-70
references: 16467336